All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Phosplatin Therapeutics have announced that their small molecule conjugate of pyrophosphate and platinum, PT-112, has been granted orphan drug designation by the US Food and Drug Administration (FDA). This status ensures financial incentives for companies developing drugs for rare, yet life-threatening conditions.
The drug is now being tested in phase I/II clinical trials as a single agent for the treatment of Relapsed and Refractory Multiple Myeloma (RRMM). The mechanism of action is thought to rely on damage associated molecular patters (DAMPs) that lead to T-cell activation, in particular in the bone marrow, making it a good candidate for MM. Pre-clinical data was presented at both ASCO and ASH in 2017, and early dosing studies that have tested the drug with solid tumors indicate a good overall tolerance. The agent is expected to lead to lower toxicity and less resistance than other chemotherapeutics.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox